Hyperbaric Oxygen Therapy for Parkinson’s disease via modulation of gut microbiota
Objective: To investigate the effect of hyperbaric oxygen therapy (HBOT) on gut microbiota in a preclinical model of PD. Background: Humans have coevolved with complex…Alpha-Synuclein Aggregates in the Olfactory Epithelium of Subjects with Parkinson Disease, Dementia, COVID-19, and in Aged Controls
Objective: We sought to examine whether neuroepithelial structures of the nasal cavity differ between individuals diagnosed with a Lewy body disorder vs those with COVID19…Utilization of Phosphorylated Alpha-Synuclein Skin Biopsy Testing in a Movement Disorders Center
Objective: To describe the utilization patterns of skin biopsy for phosphorylated alpha-synuclein (P-syn) aggregation obtained from three sites (posterior cervical, distal thigh, distal leg) and…Multimodal Sensing-Enabled Diagnosis and Assessment of Parkinson’s Disease via Biomolecule and Biomechanics Signals
Objective: The objective of this study was to develop a non-invasive, dual-mode sensing system for the early diagnosis and progression tracking of Parkinson’s disease (PD)…Influence of Gut Microbiota-Derived TMAO on Disease Severity in Parkinson’s Disease
Objective: This study aims to investigate how gut microbiota composition influences trimethylamine N-oxide (TMAO) levels in PD patients and whether TMAO and gut microbiota composition…The Syn-D Study: Detection of Cutaneous Phosphorylated Alpha-Synuclein and blood P-Tau 217 in Patients with Mild Cognitive Impairment
Objective: To quantify the deposition of cutaneous P-SYN and blood P-Tau 217 in patients with suspected DLB and AD at the mild cognitive impairment (MCI)…Repeated Scanning Ultrasound in an Alpha-synuclein Preformed Fibril model
Objective: To investigate the therapeutic potential of repeated scanning ultrasound (SUS)-mediated blood-brain barrier (BBB) opening in a mouse model of Parkinson’s disease (PD). Background: PD…Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics
Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…Clinical Characteristics of Sporadic Parkinson’s Disease with Negative CSF Alpha-synuclein Seed Amplification Assay
Objective: Define clinical characteristics of individuals with sporadic Parkinson’s disease (sPD) enrolled in the Parkinson’s Progression Markers Initiative (PPMI) who have a negative CSF alpha-synuclein…The Role of Autophagy Lysosomal and Ubiquitin Proteasomal System in the Pathophysiology of Parkinson’s disease.
Objective: The research how to better understand the molecular mechanism initiating the etiology of Parkinson's disease in order to appropriate the precise diagnosis and therapeutic…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 60
- Next Page »